Abstract: The present disclosure provides pharmaceutical compositions comprising mometasone and diisopropyl adipate (DIPA) for topical administration. These compositions can be formulated as creams, lotions, and foams, and are particularly suitable for administration in hairy skin; for example, for treating inflammatory skin conditions, such as dermatitis, eczema, and psoriasis.

Abstract: A muffler for an exhaust gas system of an internal combustion engine, the muffler including a muffler housing, at least one exhaust gas inlet, at least one gas outlet and at least one muffling device arranged in the muffler housing. At least one cooling element arranged in the muffler housing is configured to extract heat energy from the exhaust gas and is arranged in the muffler housing.

Abstract: The present invention relates to a topical pharmaceutical composition comprising, based on the total weight of the composition: a) from 1.5 wt. % to 5 wt. % of terbinafine or any pharmaceutically acceptable salt thereof; b) from 15 wt. % to 35 wt. % of urea; and c) more than 25 wt. % of water.

Abstract: An active sound generation device for exhaust gas systems of motor vehicles having a housing and a sound generation means arranged in the housing, in particular a loudspeaker, with a closed sound generation surface and a margin sealingly surrounding the sound generation surface, wherein, for the reduction of the manufacturing costs, the housing has an at least sectionally cylindrical shape and the inner diameter of the cylindrical shape corresponds to the projection of the outer periphery of the margin surrounding the sound generation surface onto a surface perpendicular to the cylinder axis such that the sound generation means can be inserted in a gas-tight manner at any desired point of the cylindrical section.

Abstract: A muffler for an exhaust gas system of an internal combustion engine, the muffler including a muffler housing, at least one exhaust gas inlet, at least one gas outlet and at least one muffling device arranged in the muffler housing. At least one cooling element arranged in the muffler housing is configured to extract heat energy from the exhaust gas and is arranged in the muffler housing.

Abstract: The present invention relates to pharmaceutical compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide, to the use of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide and compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide in therapeutic applications, especially indications with a dysregulation/overexpression of VEFG, (neo)-vascularisation and VEGF driven angiogenesis and to methods for manufacturing such compositions, the invention further relates to specific forms of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide and to the manufacturing and use of such forms. The present invention also relates to a new process to produce 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide.

Abstract: Solid dispersion comprising (4R)-4-[N?-methyl-N?-(3,5-bistrifluoromethyl-benzoyl)-amino]-4-(3,4-dichlorobenzyl)-but-2-enoic acid N—[(R)-epsilon-caprolactam-3-yl]-amide or a pharmaceutically acceptable salt or solvate thereof and a carrier. Pharmaceutical compositions comprising such solid dispersion are useful to treat patients who have functional motility disorders of the viscera, especially irritable bowel syndrome or functional dyspepsia, or urinary bladder disorders, especially urinary incontinence.